← Back to Analyst Consensus 
NVCT Buy
Nuvectis Pharma, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 24, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Jul 6, 2026 | Roth Capital | maintain | Buy → Buy | — | 53% |
| Jun 22, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 12, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 4, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Apr 30, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Apr 2, 2025 | Maxim Group | initiate | — → Buy | $17 | 42% |
| Mar 17, 2025 | Laidlaw & Co. | initiate | — → Buy | $19 | 20% |
| Feb 25, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $11 | 44% |
| Aug 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| May 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Sep 15, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Mar 7, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $21 | 44% |
| Feb 10, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $21 | 44% |
| Jul 13, 2022 | Ladenburg Thalmann | initiate | — → Buy | $21 | 45% |
| May 10, 2022 | HC Wainwright & Co. | maintain | — → Buy | $21 | 44% |
| Mar 2, 2022 | HC Wainwright & Co. | initiate | — → Buy | $14 | 44% |
Price Target Trend
Apr 24, 2026 Latest: $35.4 Oct 23, 2026
EPS Estimates
+1q $-0.25
Lo: $-0.33 Hi: $-0.20
6 analysts ▲1
+1y $-1.15
Lo: $-1.62 Hi: $-0.82
6 analysts 0y $-1.04
Lo: $-1.17 Hi: $-0.94
6 analysts ▲1
0q $-0.24
Lo: $-0.28 Hi: $-0.21
6 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days